The strong clinical data could lead to accelerated regulatory approval and commercialization. Traders should monitor for potential partnership announcements or licensing deals with larger pharmaceutical companies.
Price Chart
Executive Summary
PDS Biotechnology announced positive interim Phase 2 clinical trial data for its drug PDS01ADC in treating metastatic colorectal cancer, showing a 78% objective response rate and 85% 2-year survival rate compared to 35% in a parallel trial.
Key Facts
- PDS01ADC showed 77.8% objective response rate (ORR) at 6 months vs 35% in parallel trial
- 24-month survival rate was approximately 85% vs 40% in parallel trial
- Data published in Journal of Clinical Oncology (JCO) Oncology Advances
- Trial conducted in unresectable microsatellite stable (MSS) or mismatch repair-proficient p(MMR) colorectal liver metastases
- PDS01ADC is a tumor-targeted immunocytokine designed to deliver Interleukin-12 (IL-12) directly to tumors
Financial Impact
Significant improvement in clinical outcomes with 77.8% ORR vs 35% in control group and 85% 2-year survival vs 40% in control group
Risk Factors
- Phase 2 data is still preliminary and may not translate to Phase 3 success
- Competitors in the colorectal cancer space could impact market potential
- The company's small market cap ($59M) makes it vulnerable to volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-014693 |
| Document: ef20070560_ex99-1.htm | 0001140361-26-014693 |
| Document: 0001140361-26-014693-index-headers.html | 0001140361-26-014693 |
| Document: 0001140361-26-014693-index.html | 0001140361-26-014693 |
| Document: 0001140361-26-014693.txt | 0001140361-26-014693 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | 8-K | $0.3000 $0.5853 | ▼ −95.10% | ▼ −96.22% | $0.7366 (−145.53%) |
Aug 19, 2026 6w ago | 8-K | $0.2089 $0.2179 | ▲ +4.31% | ▲ +3.19% | $0.7366 (+252.61%) |
Aug 13, 2026 7w ago | 8-K | $0.2332 $0.2089 | ▲ +10.42% | ▲ +8.46% | $0.7366 (−215.87%) |
Aug 11, 2026 7w ago | 8-K | $0.2570 $0.2080 | ▲ +19.07% | ▲ +18.66% | $0.7366 (−186.61%) |
Jul 22, 2026 10w ago | EFFECT | $0.7155 $0.6696 | ▲ +6.42% | ▲ +4.01% | $0.7366 (−2.95%) |
Jun 26, 2026 13w ago | DEFA14A | $0.8991 $0.8461 | ▼ −5.89% | ▼ −7.28% | $0.7366 (−18.07%) |
Jun 15, 2026 15w ago | 8-K | $0.9600 $0.9120 | ▲ +5.00% | ▲ +2.77% | $0.7366 (+23.27%) |
Jun 15, 2026 15w ago | 8-K | $1.02 $0.9412 | ▼ −7.73% | ▼ −6.34% | $0.7366 (−27.78%) |
Jun 2, 2026 17w ago | 8-K | $1.16 $1.03 | ▼ −11.21% | ▼ −8.24% | $0.7366 (−36.50%) |
May 13, 2026 20w ago | Press Release | $1.33 $1.00 | ▼ −24.81% | ▼ −23.65% | $0.7366 (−44.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access